Literature DB >> 18548330

Pulmonary embolism after tadalafil ingestion.

Huang-Chi Chen1, Chuan-Sheng Wang, Shu-Hui Chuang, Cheng-Yuan Wang.   

Abstract

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor that is used to treat male erectile dysfunction. It is currently undergoing clinical trials for the treatment of pulmonary hypertension. Although at present there is no evidence of hypercoagulation states being associated with the use of PDE5 inhibitors, several studies suggest that PDE5 inhibitors may, in rare cases, cause arterial and venous thrombotic or embolic events in the heart, eye, brain, and ear. We report a 54-year-old male patient with reduced plasma levels of protein C who developed pulmonary embolism (PE) just after he started taking tadalafil. The Naranjo probability scale indicates tadalafil as the possible cause of a PE in our patient. To the best of our knowledge, this is the first case report of tadalafil-induced PE in the literature.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18548330     DOI: 10.1007/s11096-008-9229-0

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  15 in total

1.  Branch retinal artery occlusion; another complication of sildenafil.

Authors:  A Tripathi; N P O'Donnell
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

2.  Acute myocardial infarction associated with sildenafil.

Authors:  J Feenstra; R J van Drie-Pierik; C F Laclé; B H Stricker
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

3.  Anterior ischemic optic neuropathy associated with viagra.

Authors:  A V Cunningham; K H Smith
Journal:  J Neuroophthalmol       Date:  2001-03       Impact factor: 3.042

4.  Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.

Authors:  I V Turko; S A Ballard; S H Francis; J D Corbin
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

Review 5.  Overall cardiovascular profile of sildenafil citrate.

Authors:  R M Zusman; A Morales; D B Glasser; I H Osterloh
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

6.  High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.

Authors:  Jackie D Corbin; Alfreda Beasley; Mitsi A Blount; Sharron H Francis
Journal:  Biochem Biophys Res Commun       Date:  2005-09-02       Impact factor: 3.575

7.  Transient ischemic attack and stroke associated with sildenafil (Viagra) use.

Authors:  J C Morgan; M Alhatou; J Oberlies; K C Johnston
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

8.  Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction.

Authors:  A Rufa; A Cerase; L Monti; M T Dotti; A Giorgio; F Sicurelli; A Federico
Journal:  J Neurol Sci       Date:  2007-06-18       Impact factor: 3.181

9.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

Review 10.  Versatile effects of sildenafil: recent pharmacological applications.

Authors:  Subramaniam Uthayathas; Senthilkumar S Karuppagounder; Bessy M Thrash; Kodeeswaran Parameshwaran; Vishnu Suppiramaniam; Muralikrishnan Dhanasekaran
Journal:  Pharmacol Rep       Date:  2007 Mar-Apr       Impact factor: 3.024

View more
  2 in total

1.  A case of acute pulmonary thromboembolism after taking tadalafil.

Authors:  Jinwoo Lee; Ji Hyun Kwon; Chang-Hoon Lee; Sang-Min Lee; Jae-Joon Yim; Chuy-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young Sik Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-10-31

2.  The Development of Cerebral Venous Thrombosis after Tadalafil Ingestion in a Patient with Antiphospholipid Syndrome.

Authors:  Kenji Numata; Kouhei Shimoda; Yasushi Shibata; Ayako Shioya; Yasuharu Tokuda
Journal:  Intern Med       Date:  2017-05-15       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.